Animal experiment:

Mice[1]In this 10-day supplementation experiment, mice (n = 10/group) receive the following: 1) as a control group, only the vehicle for dissolution of Esomeprazole (PEG-400) given orally once daily by gastric gavage; 2) Esomeprazole 0.5 mg/kg in an equivalent volume of PEG-400 given orally once daily by gastric lavage; 3) Esomeprazole 5 mg/kg in an equivalent volume of PEG-400 given orally once daily by gastric lavage; and 4) Esomeprazole 50 mg/kg in an equivalent volume of PEG-400 given orally once daily by gastric lavage[1].

Esomeprazole magnesium is an inhibitor of H+, K+-ATPase, effectively used in the research of upper intestinal disorder.

Esomeprazole magnesium is an inhibitor of H+, K+-ATPase[1].

Esomeprazole magnesium (0.5, 5, 50 mg/kg/day, p.o.) produces increased gastric total antioxidant capacity, decreases gastric lipid peroxide levels, significantly increases superoxide dismutase levels, but shows no obvious effect on colonic lipid peroxide levels in mice[1].

References:
[1]. Koch TR, et al. Effect of the H, K-ATPase inhibitor, esomeprazole magnesium, on gut total antioxidant capacity in mice. J Nutr Biochem. 2004 Sep;15(9):522-6.